FDA approves Tarsus' XDEMVY (lotilaner) 0.25% for Demodex blepharitis

Tarsus Pharmaceuticals, Inc.

FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for treatment of Demodex blepharitis.
Approval announced July 25, 2023 via press release and investor webcast.
Corporate presentation and webcast replay posted on Tarsus' investor website.

item 7.01

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-192827

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.